Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Atraumatic osteonecrosis of the humeral head after influenza A-(H1N1) v-2009 vaccination.

Kuether G, Dietrich B, Smith T, Peter C, Gruessner S.

Vaccine. 2011 Sep 16;29(40):6830-3. doi: 10.1016/j.vaccine.2011.07.052. Epub 2011 Jul 29.

PMID:
21803092
2.

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.

Carmona A, Omeñaca F, Tejedor JC, Merino JM, Vaman T, Dieussaert I, Gillard P, Arístegui J.

Vaccine. 2010 Aug 16;28(36):5837-44. doi: 10.1016/j.vaccine.2010.06.065. Epub 2010 Jun 29.

PMID:
20600478
3.

The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic.

Engelhard D, Zakay-Rones Z, Shapira MY, Resnick I, Averbuch D, Grisariu S, Dray L, Djian E, Strauss-Liviatan N, Grotto I, Wolf DG, Or R.

Vaccine. 2011 Feb 17;29(9):1777-82. doi: 10.1016/j.vaccine.2010.12.113. Epub 2011 Jan 7.

PMID:
21216315
4.

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.

Vaccine. 2010 Jan 8;28(3):849-57. doi: 10.1016/j.vaccine.2009.10.017. Epub 2009 Oct 14.

PMID:
19835828
5.

Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.

Lagler H, Wenisch JM, Tobudic S, Gualdoni GA, Rödler S, Rasoul-Rockenschaub S, Jaksch P, Redlberger-Fritz M, Popow-Kraupp T, Burgmann H.

Vaccine. 2011 Sep 16;29(40):6888-93. doi: 10.1016/j.vaccine.2011.07.050. Epub 2011 Jul 29.

PMID:
21803100
6.

Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.

Andrews NJ, Walker WT, Finn A, Heath PT, Collinson AC, Pollard AJ, Snape MD, Faust SN, Waight PA, Hoschler K, Sheasby L, Waddington C, Kerridge S, Chalk J, Reiner A, John T, Fletcher M, Allen R, Fineman N, Wilkins S, Casey M, Michaelis L, Oeser C, Okike I, Ladhani S, Miller E.

Vaccine. 2011 Oct 19;29(45):7913-9. doi: 10.1016/j.vaccine.2011.08.076. Epub 2011 Aug 27.

PMID:
21875635
7.

AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.

Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P.

Clin Infect Dis. 2010 Sep 15;51(6):668-77. doi: 10.1086/655830.

PMID:
20687838
8.

Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan.

Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Maeda A, Li P, Gillard P, Roman F.

Hum Vaccin. 2010 Nov;6(11):888-93. Epub 2010 Nov 1.

PMID:
20980795
9.

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.

Banzhoff A, Haertel S, Praus M.

Hum Vaccin. 2011 May;7(5):539-48. Epub 2011 May 1.

PMID:
21422814
10.

Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis.

Beyer WE, Nauta JJ, Palache AM, Giezeman KM, Osterhaus AD.

Vaccine. 2011 Aug 5;29(34):5785-92. doi: 10.1016/j.vaccine.2011.05.040. Epub 2011 May 30. Review.

PMID:
21624411
11.

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.

Vaccine. 2010 Feb 17;28(7):1740-5. doi: 10.1016/j.vaccine.2009.12.014. Epub 2009 Dec 22.

PMID:
20034605
12.

Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients.

Meyer S, Adam M, Schweiger B, Ilchmann C, Eulenburg C, Sattinger E, Runte H, Schlüter M, Deuse T, Reichenspurner H, Costard-Jäckle A.

Transplantation. 2011 May 15;91(9):1031-5. doi: 10.1097/TP.0b013e3182115be0.

PMID:
21358365
13.

Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort.

Schuurmans MM, Tini GM, Dalar L, Fretz G, Benden C, Boehler A.

J Heart Lung Transplant. 2011 Jun;30(6):685-90. doi: 10.1016/j.healun.2011.01.707. Epub 2011 Mar 27. Erratum in: J Heart Lung Transplant. 2011 Oct;30(10):1206.

PMID:
21444211
14.

Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children.

Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Langley JM, Dobson S, Li Y, Law B, Halperin SA; Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Rapid Trials Investigators.

Pediatr Infect Dis J. 2011 May;30(5):402-7. doi: 10.1097/INF.0b013e3182068f33.

PMID:
21178654
15.

An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients.

Esposito S, Meregalli E, Daleno C, Ghio L, Tagliabue C, Valzano A, Serra D, Galeone C, Edefonti A, Principi N.

Nephrol Dial Transplant. 2011 Jun;26(6):2018-24. doi: 10.1093/ndt/gfq657. Epub 2010 Oct 25.

PMID:
20974645
16.

Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.

Girard MP, Katz JM, Pervikov Y, Hombach J, Tam JS.

Vaccine. 2011 Oct 13;29(44):7579-86. doi: 10.1016/j.vaccine.2011.08.031. Epub 2011 Aug 19.

PMID:
21856358
17.

Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents.

Garcia-Sicilia J, Gillard P, Carmona A, Tejedor JC, Aristegui J, Merino JM, Behre U, Caplanusi A, Vaman T, Dieussaert I.

Vaccine. 2011 Jun 10;29(26):4353-61. doi: 10.1016/j.vaccine.2011.04.011. Epub 2011 Apr 17.

PMID:
21504774
18.

Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine.

Gagnon R, Primeau MN, Des Roches A, Lemire C, Kagan R, Carr S, Ouakki M, Benoît M, De Serres G; PHAC-CIHR Influenza Research Network.

J Allergy Clin Immunol. 2010 Aug;126(2):317-23. doi: 10.1016/j.jaci.2010.05.037. Epub 2010 Jun 25.

PMID:
20579720
19.

Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.

Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, Mosca F, Principi N.

Pediatrics. 2011 May;127(5):e1161-8. doi: 10.1542/peds.2010-1920. Epub 2011 Apr 4.

PMID:
21464195
20.

Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in haemodialysed patients.

Labriola L, Hombrouck A, Maréchal C, Van Gucht S, Brochier B, Thomas I, Jadoul M, Goubau P.

Nephrol Dial Transplant. 2011 Apr;26(4):1424-8. doi: 10.1093/ndt/gfq782. Epub 2011 Jan 27.

PMID:
21273236

Supplemental Content

Support Center